BioMedPartners
Venture capitalBasel · Seed–Late Stage · 28 people tracked
Investment thesis
BiomedVC backs the next generation of European life science entrepreneurs, helping translate scientific innovation from academic labs into venture-backed biotechs developing therapeutics for high-unmet medical needs. The firm makes initial Seed and Series A investments, leads and co-leads rounds, and reserves capital for follow-on financings. It focuses on continental Europe with an emphasis on the DACH region, particularly Switzerland and Germany. BiomedVC continues the legacy of predecessor BioMedPartners, one of the earliest life-science-focused early-stage VCs in continental Europe. The firm is raising its new fund, BiomedInvest IV, and has already built a significant portfolio of biotech start-ups in Switzerland and Germany.
Source: firm website, verified Aug 7, 2026.
Team · 28 people
from the firm's website & curated & public directories
What they invest in
from 8 of 21 portfolio companiesBiotech ×8Healthtech ×7Medical Devices ×5AI & Machine Learning ×2Deep Tech ×2Digital Health ×1Hardware ×1
HQs:Switzerland×1Germany×1France×1Netherlands×1
Investments · 21 tracked
founders shown can be your intro path
Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.
AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH
Thomas Baumert(Founder)Mark Pruzanski(Chief Executive Officer)Luigi Manenti(Chief Medical Officer)Jon Freve(Chief Financial Officer)Bryan Yoon(General Counsel and Chief Administrative Officer)inAditya Venugopal(Chief Business Officer)
Co-investorsAvego BioScience CapitalFrazier Life SciencesJeito CapitalLongitude CapitalNovo HoldingsOrbiMed+5 more
Azafaros is a clinical-stage biopharmaceutical company developing small-molecule therapies for severe rare genetic metabolic disorders, including GM1/GM2 gangliosidoses, Niemann-Pick type C disease, and other conditions.
BiotechDeep TechHealthtechMedical DevicesLeiden, NL
Hans Aerts(Professor)Hermen Overkleeft(Professor)Stan van Boeckel(Professor)
Co-investorsForbionJeito CapitalBioGeneration VenturesPictet GroupSeroba Life Sciences
Co-investorsAndera PartnersDelos Capital
Co-investors3B Future Health Fund
Co-investorsInkefSunstone Capital
A private biotech company developing crosslinked helix dimers as therapeutics targeting intracellular protein-protein interactions.
Co-investorsCARMA FUND
Developing a targeted intracellular drug delivery platform with an oncology pipeline.
Immunos Therapeutics develops therapies for immuno-oncology and inflammatory diseases.
BiotechHealthtechMedical Devices
Co-investorsLightspeed Venture PartnersMission BiocapitalPfizer Venture InvestmentsPfizer Venturesredalpine
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.
BiotechHealthtechMedical Devices
Ilise Lombardo(Chief Executive Officer)Volker Knappertz(Executive Vice President of Research & Development)Michael Samar(Chief Financial Officer)Rob Lasser(Chief Medical Officer)
Co-investorsJeito CapitalRoche Venture FundSofinnova PartnersEQTEQT Life SciencesForbion+2 more
Immunotherapies for T cell-mediated autoimmune conditions via modulation of coronin 1; spin-off from the University of Basel.
Co-investorsKickfund
Develops novel therapeutics through protein, DNA, and RNA engineering.
Co-investorsHealthCapPontifax Venture CapitalV-Bio VenturesInkef
Company developing novel TNF-targeting antibodies with selective epitope technology for improved therapeutic benefit-risk profiles and bispecific therapies.
Co-investorsCARMA FUND
Scenic Biotech develops modifier therapy, a genetic medicine approach that targets secondary functions in the genome to neutralize the impact of disease-causing mutations.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtech
Co-investorsEIR VenturesOxford Science EnterprisesBioGeneration VenturesInkef
Clinical-stage CAR-T programs with a proprietary non-viral in vivo CAR-T platform.
TOLREMO therapeutics develops small molecule inhibitors targeting transcriptional resistance mechanisms in cancer, with a lead clinical candidate TT125-802 designed for solid tumors and hematological malignancies as both monotherapy and combination treatment.
Biotech
Co-investorsredalpine
Topas Therapeutics develops nanoparticle-based therapies to induce immune tolerance for autoimmune and immune-mediated diseases.
BiotechHealthtech
Hugo Fry(Chief Executive Officer)Christian Schröter(Chief Operating Officer)Cristina de Min(Chief Medical Officer)Anne Burger(Chief Financial Officer)Alex Marshall(Chief Business Officer)
Co-investorsEMBL VenturesBoehringer Ingelheim Venture FundGimvEpidarex Capital
TRiCares develops the Topaz Transfemoral Tricuspid Heart Valve Replacement (TTVR) System, a minimally invasive device for treating tricuspid regurgitation.
BiotechHardwareHealthtechMedical DevicesFrance, FR
Ahmed Elmouelhi(President & CEO)Esther Gerteis(Senior VP Medical & Regulatory Affairs)Michael Litzenburger(VP R&D)
Co-investorsEuropean Investment Bank415 CapitalAndera PartnersBayern KapitalKarista
The page is a placeholder shell showing only cookie/consent notices for embedded third-party content (Vimeo, YouTube, reCAPTCHA, social media) and contains no substantive information about the company.
Dominik Schumacher(Founder)in
Co-investorsAndera PartnersFrazier Life SciencesFund+Nextech InvestOCCIDENT
Exits · 1
IPOs and acquisitions across the tracked portfolioTubulis GmbHacq. by Gilead Sciences
Portfolio news
latest coverage across their companiesAlentis · biopharminternational.com · Jun 29, 2026
Noema Pharma · s-ge.com · Nov 4, 2025
Azafaros · siliconcanals.com · May 14, 2025
Frequently asked questions
- How many investments has BioMedPartners made?
- BioMedPartners has 21 tracked investments, 1 of which have exited via acquisition or IPO.
- What stage does BioMedPartners invest at?
- BioMedPartners invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What is BioMedPartners's typical check size?
- BioMedPartners typically writes checks of $648K – $6.5M.
- What sectors does BioMedPartners focus on?
- BioMedPartners focuses on Biotech, Healthtech, Medical Devices.
- Where is BioMedPartners located?
- BioMedPartners is headquartered in Basel, CH.
- Does BioMedPartners lead rounds?
- Yes, BioMedPartners leads investment rounds.
- Who does BioMedPartners co-invest with?
- BioMedPartners most often shares deals with Andera Partners, Jeito Capital, CARMA FUND, among 34 tracked co-investors.
Images
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Pappas Capital is a life sciences venture capital firm that invests in and helps build companies developing next-generation life science products and technologies.
Korea Investment Partners is a South Korea-based venture capital firm that invests across multiple stages from early-stage startups through growth and buyout transactions, including venture debt and mezzanine financing. The firm operates across venture capital, middle market, and growth equity investment categories.
JSTAR Capital Investments is a healthcare-focused investment firm backing medical technology companies, providing capital and expert guidance to advance patient care and address global healthcare challenges.
New Science Ventures (NSV) is a venture capital firm based in Connecticut and London that backs companies applying novel scientific approaches in the life sciences and information technology sectors.